Kane Biotech Inc. (KNBIF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 5.68 Million CAD | 1.09% |
| 2022 | 5.61 Million CAD | -8.39% |
| 2021 | 6.13 Million CAD | 21.82% |
| 2020 | 5.03 Million CAD | 82.74% |
| 2019 | 2.75 Million CAD | 77.11% |
| 2018 | 1.55 Million CAD | -54.2% |
| 2017 | 3.39 Million CAD | 59.4% |
| 2016 | 2.13 Million CAD | 81.67% |
| 2015 | 1.17 Million CAD | -41.03% |
| 2014 | 1.98 Million CAD | 5.62% |
| 2013 | 1.88 Million CAD | -25.4% |
| 2012 | 2.52 Million CAD | 2.19% |
| 2011 | 2.47 Million CAD | 96.98% |
| 2010 | 1.25 Million CAD | -32.78% |
| 2009 | 1.86 Million CAD | 18.67% |
| 2008 | 1.57 Million CAD | 27.98% |
| 2007 | 1.22 Million CAD | -19.04% |
| 2006 | 1.51 Million CAD | 31.73% |
| 2005 | 1.15 Million CAD | 118.87% |
| 2004 | 526.37 Thousand CAD | -48.0% |
| 2003 | 1.01 Million CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 5.79 Million CAD | 2.07% |
| 2024 Q2 | 4.07 Million CAD | -29.74% |
| 2023 Q4 | 5.68 Million CAD | -5.49% |
| 2023 Q3 | 6.01 Million CAD | 7.68% |
| 2023 Q1 | 5.46 Million CAD | -2.75% |
| 2023 FY | 5.68 Million CAD | 1.09% |
| 2023 Q2 | 5.58 Million CAD | 2.14% |
| 2022 Q2 | 7.41 Million CAD | 30.53% |
| 2022 FY | 5.61 Million CAD | -8.39% |
| 2022 Q1 | 5.67 Million CAD | -7.42% |
| 2022 Q3 | 6.59 Million CAD | -11.03% |
| 2022 Q4 | 5.61 Million CAD | -14.79% |
| 2021 FY | 6.13 Million CAD | 21.82% |
| 2021 Q2 | 5.73 Million CAD | 28.56% |
| 2021 Q3 | 6.54 Million CAD | 14.02% |
| 2021 Q4 | 6.13 Million CAD | -6.21% |
| 2021 Q1 | 4.46 Million CAD | -11.39% |
| 2020 FY | 5.03 Million CAD | 82.74% |
| 2020 Q1 | 2.53 Million CAD | -7.93% |
| 2020 Q2 | 2.66 Million CAD | 5.07% |
| 2020 Q3 | 4.88 Million CAD | 83.31% |
| 2020 Q4 | 5.03 Million CAD | 3.05% |
| 2019 Q1 | 1.63 Million CAD | 5.38% |
| 2019 FY | 2.75 Million CAD | 77.11% |
| 2019 Q3 | 2.1 Million CAD | -26.21% |
| 2019 Q2 | 2.85 Million CAD | 74.32% |
| 2019 Q4 | 2.75 Million CAD | 30.66% |
| 2018 Q3 | 1.56 Million CAD | -9.95% |
| 2018 Q2 | 1.73 Million CAD | -36.12% |
| 2018 FY | 1.55 Million CAD | -54.2% |
| 2018 Q4 | 1.55 Million CAD | -0.65% |
| 2018 Q1 | 2.72 Million CAD | -19.85% |
| 2017 Q2 | 1.75 Million CAD | -13.96% |
| 2017 Q1 | 2.03 Million CAD | -4.51% |
| 2017 Q4 | 3.39 Million CAD | -14.65% |
| 2017 FY | 3.39 Million CAD | 59.4% |
| 2017 Q3 | 3.98 Million CAD | 127.3% |
| 2016 Q2 | 3.26 Million CAD | 129.59% |
| 2016 FY | 2.13 Million CAD | 81.67% |
| 2016 Q1 | 1.42 Million CAD | 21.14% |
| 2016 Q4 | 2.13 Million CAD | -21.06% |
| 2016 Q3 | 2.69 Million CAD | -17.25% |
| 2015 Q2 | 1.3 Million CAD | -18.84% |
| 2015 Q1 | 1.61 Million CAD | -18.97% |
| 2015 Q3 | 1.22 Million CAD | -6.13% |
| 2015 Q4 | 1.17 Million CAD | -4.48% |
| 2015 FY | 1.17 Million CAD | -41.03% |
| 2014 Q3 | 1.25 Million CAD | -8.95% |
| 2014 Q4 | 1.98 Million CAD | 58.05% |
| 2014 Q1 | 1.87 Million CAD | -0.55% |
| 2014 FY | 1.98 Million CAD | 5.62% |
| 2014 Q2 | 1.38 Million CAD | -26.19% |
| 2013 Q1 | 2.06 Million CAD | -18.37% |
| 2013 FY | 1.88 Million CAD | -25.4% |
| 2013 Q4 | 1.88 Million CAD | 28.79% |
| 2013 Q3 | 1.46 Million CAD | -14.3% |
| 2013 Q2 | 1.7 Million CAD | -17.2% |
| 2012 Q2 | 1.84 Million CAD | -14.38% |
| 2012 Q1 | 2.15 Million CAD | -12.64% |
| 2012 FY | 2.52 Million CAD | 2.19% |
| 2012 Q4 | 2.52 Million CAD | 69.57% |
| 2012 Q3 | 1.48 Million CAD | -19.44% |
| 2011 Q2 | 2.95 Million CAD | 162.71% |
| 2011 Q1 | 1.12 Million CAD | -10.46% |
| 2011 Q4 | 2.47 Million CAD | -8.69% |
| 2011 FY | 2.47 Million CAD | 96.98% |
| 2011 Q3 | 2.7 Million CAD | -8.29% |
| 2010 Q4 | 1.25 Million CAD | 4.94% |
| 2010 Q2 | 1.41 Million CAD | -15.49% |
| 2010 FY | 1.25 Million CAD | -32.78% |
| 2010 Q3 | 1.19 Million CAD | -15.61% |
| 2010 Q1 | 1.67 Million CAD | -10.17% |
| 2009 Q1 | 1.33 Million CAD | -15.08% |
| 2009 FY | 1.86 Million CAD | 18.67% |
| 2009 Q4 | 1.86 Million CAD | 42.47% |
| 2009 Q3 | 1.3 Million CAD | -0.71% |
| 2009 Q2 | 1.31 Million CAD | -1.2% |
| 2008 FY | 1.57 Million CAD | 27.98% |
| 2008 Q4 | 1.57 Million CAD | -6.77% |
| 2008 Q3 | 1.68 Million CAD | -21.2% |
| 2008 Q2 | 2.14 Million CAD | -13.8% |
| 2008 Q1 | 2.48 Million CAD | 102.09% |
| 2007 FY | 1.22 Million CAD | -19.04% |
| 2007 Q1 | 1.27 Million CAD | -15.9% |
| 2007 Q2 | 1.04 Million CAD | -18.26% |
| 2007 Q3 | 1.39 Million CAD | 33.59% |
| 2007 Q4 | 1.22 Million CAD | -11.84% |
| 2006 Q2 | 2.04 Million CAD | 101.89% |
| 2006 Q1 | 1.01 Million CAD | -11.91% |
| 2006 FY | 1.51 Million CAD | 31.73% |
| 2006 Q4 | 1.51 Million CAD | -17.75% |
| 2006 Q3 | 1.84 Million CAD | -9.95% |
| 2005 Q4 | 1.15 Million CAD | -12.05% |
| 2005 Q1 | 1.81 Million CAD | 244.43% |
| 2005 Q2 | 1.59 Million CAD | -11.82% |
| 2005 FY | 1.15 Million CAD | 118.87% |
| 2005 Q3 | 1.3 Million CAD | -18.07% |
| 2004 Q1 | 932.71 Thousand CAD | -7.86% |
| 2004 Q4 | 526.37 Thousand CAD | -16.42% |
| 2004 Q3 | 629.79 Thousand CAD | -16.45% |
| 2004 Q2 | 753.81 Thousand CAD | -19.18% |
| 2004 FY | 526.37 Thousand CAD | -48.0% |
| 2003 FY | 1.01 Million CAD | 0.0% |
| 2003 Q4 | 1.01 Million CAD | -5.01% |
| 2003 Q2 | 821.77 Thousand CAD | 0.0% |
| 2003 Q3 | 1.06 Million CAD | 29.68% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ContraFect Corporation | 20.67 Million USD | 72.528% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 85.376% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 21.314% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -7340.238% |
| SQZ Biotechnologies Company | 107.18 Million USD | 94.7% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -296.703% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 46.173% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 95.637% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -7750.368% |
| Marizyme, Inc. | 22.01 Million USD | 74.195% |
| Genus plc | 1.02 Billion USD | 99.448% |
| Pharming Group N.V. | 462.85 Million USD | 98.773% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -71.473% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1038.372% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -806.048% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -1386.463% |
| IMV Inc. | 31.33 Million USD | 81.87% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -37.021% |
| ONE Bio Corp. | 70.08 Million USD | 91.894% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 95.579% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -637.165% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -2074.29% |
| Biomind Labs Inc. | 73.81 Thousand USD | -7595.741% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 98.727% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 81.073% |
| Skye Bioscience, Inc. | 11.94 Million USD | 52.423% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Mesoblast Limited | 667.9 Million USD | 99.149% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -106.855% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -190.111% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -726.332% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -118.229% |
| GB Sciences, Inc. | 103.44 Thousand USD | -5391.888% |
| MultiCell Technologies, Inc. | 126.22 USD | -4500707.321% |
| Alpha Cognition Inc. | 2.45 Million USD | -131.669% |
| HST Global, Inc. | 1526.00 USD | -372175.164% |
| CSL Limited | 38.02 Billion USD | 99.985% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Agentix Corp. | 261.39 Thousand USD | -2073.333% |
| Halberd Corporation | 10.13 Thousand USD | -55974.613% |
| Enzolytics Inc. | 361.7 Million USD | 98.429% |
| Resverlogix Corp. | 8.11 Million USD | 29.995% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -202.518% |
| argenx SE | 4.54 Billion USD | 99.875% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 88.091% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 83.851% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 36.52% |
| Bioxytran, Inc. | 137.63 Thousand USD | -4027.435% |
| Zenith Capital Corp. | 7410.00 USD | -76565.574% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -1665.324% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -2073.566% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -512.194% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.832% |
| Kadimastem Ltd | 2.3 Million USD | -146.559% |
| Helix BioMedix, Inc. | 3.02 Million USD | -87.794% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -292.1% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 89.22% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -318.221% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -1355.28% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -504.553% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1215.899% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -9850.116% |
| Q BioMed Inc. | 3.51 Million USD | -61.596% |
| LadRx Corporation | 2.3 Million USD | -146.153% |
| Cell Source, Inc. | 195.17 Thousand USD | -2810.739% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1082.153% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1506.518% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 79.67% |
| Itoco Inc. | 1.4 Million USD | -305.759% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -5838.843% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -475.011% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -788.121% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -5259.358% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -24837.092% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.37 Million USD | 22.993% |
| Ember Therapeutics, Inc. | 184.00 USD | -3087355.978% |
| NovAccess Global Inc. | 62.24 Thousand USD | -9026.268% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -3873.449% |
| BioStem Technologies, Inc. | 14.56 Million USD | 60.983% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -31672.478% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -245827.229% |
| Qrons Inc. | 420.00 USD | -1352499.762% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -1373.76% |
| SYBLEU INC | 330.46 Thousand USD | -1619.053% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -928.928% |
| Rebus Holdings, Inc. | 5000.00 USD | -113518.38% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1506.518% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -1287.546% |
| Affymax, Inc. | 7.44 Million USD | 23.674% |
| Mobile Lads Corp. | 52.00 USD | -10924744.231% |
| International Stem Cell Corporation | 5.39 Million USD | -5.397% |
| CytoDyn Inc. | 11.13 Million USD | 48.986% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 62.132% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 65.734% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -7091.037% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -556.999% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 24.426% |
| Neutra Corp. | 2851.00 USD | -199160.575% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 82.47% |
| PureTech Health plc | 693.97 Million USD | 99.181% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 29.614% |
| IXICO plc | 15.84 Million USD | 64.144% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 31.406% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 94.502% |
| CSL Limited | 38.02 Billion USD | 99.985% |
| Cellectis S.A. | 333.99 Million USD | 98.299% |